Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $854.00 at Piper Sandler

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by Piper Sandler from $855.00 to $854.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on REGN. BMO Capital Markets cut their price target on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Leerink Partners reaffirmed a “market perform” rating and issued a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Canaccord Genuity Group cut their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday. Finally, Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $787.67.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of Regeneron Pharmaceuticals stock opened at $667.95 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm has a 50-day moving average of $645.74 and a 200-day moving average of $722.80. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $821.11. The stock has a market cap of $70.62 billion, a PE ratio of 16.28, a PEG ratio of 1.46 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the firm posted $8.22 EPS. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 37.4 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of REGN. WPG Advisers LLC grew its position in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at approximately $26,000. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $29,000. Finally, Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $31,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.